<DOC>
	<DOCNO>NCT01842620</DOCNO>
	<brief_summary>This open-label , single-center , randomize , 2-way crossover study evaluate bioequivalence OXEMET™ 1000 mg coat tablet , relative 1000 mg reference product administer two 500 mg tablet , fast condition , 24 healthy adult subject . Each subject receive two treatment ( Treatment A Treatment B ) . In Period 1 , subject dose either one OXEMET™ 1000 mg tablet ( Treatment A , Test ) two 500 mg tablet reference product ( GLAFORNIL™ 500 mg ) ( Treatment B , Reference ) . Following washout least 7 day , subject cross Period 2 receive treatment receive Period 1 .</brief_summary>
	<brief_title>OXEMET™ 1000 mg Coated Tablets ( Metformin Hydrochloride ) Bioequivalence Study . OXEMET ( TM ) Trademark GlaxoSmithKline Group Companies . GLAFORNIL ( TM ) Trademark Merck .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>ALT , alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Single QTc &lt; 450 msec . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 21 55 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . A female subject eligible participate childbearing potential abstinent agree use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 7 day postlast dose . Body weight &gt; 50 kg BMI within range 19 27 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive test HIV antibody . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 360 mL beer , 150 mL wine 45 mL 40 % abv distilled spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Subjects whose sit blood pressure le 110/60 mmHg screen prior dosing , great 140/90 mmHg screening . Subjects whose pulse low 50 beat per minute high 99 beat per minute screen prior dosing . Subjects whose ECG PR interval &gt; 220 msec screen prior dosing . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . History sensitivity heparin heparininduced thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>